Cancer NetworkThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

Pages: 1 2 3 4 5 6 7 8 9

421 records returned

Updated regimens on par with standard therapy in diffuse large B-cell lymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Researchers are exploring ways to manipulate rituximab (Rituxan) when added to the current standard therapy for diffuse large B-cell lymphoma, specifically shortening the number of treatment days. Preliminary results of a phase III trial showed that rituximab plus CHOP over a 14-day cycle achieved similar response rates and comparable toxicity compared to CHOP on a 21-day cycle in newly diagnosed patients. (Source: Cancer Network)
Source: Cancer Network - November 21, 2009 Category: Cancer & Oncology Source Type: info

Experts contest review article declaring breast MRI causes more harm than good by encouraging radical RxEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A review article asserting breast MRI does not improve surgical planning, reduce follow-up surgeries, or reduce the risk of local recurrences drew the ire of the breast imaging community. (Source: Cancer Network)
Source: Cancer Network - November 20, 2009 Category: Cancer & Oncology Source Type: info

JAMA article reignites debate over screeningEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In a prepared statement, Dr. Brawley said the ACS stands by its recommendation that women 40 years and older should receive annual mammography screening, and women at high risk should talk with their doctors about when screening should begin based on their family history. (Source: Cancer Network)
Source: Cancer Network - November 20, 2009 Category: Cancer & Oncology Source Type: info

Ultrasound targets lymph node recurrence in breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Ultrasound is an effective way to monitor lymph node recurrence after breast cancer surgery, South Korean researchers reported. Regional lymph node recurrence affects just 2% to 16% of patients with any stage of breast cancer, but is difficult to manage and associated with poor prognosis. (Source: Cancer Network)
Source: Cancer Network - November 20, 2009 Category: Cancer & Oncology Source Type: info

Radiation Rx prevents melanoma’s invasion of lymph nodesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CHICAGO—Radiation of the lymph nodes of high-risk melanoma patients appears to significantly reduce the risk that cancer will recur in those nodes, researchers said at ASTRO 2009. The study was deemed practice-changing, representing the first advance in the management of melanoma in nearly two decades. (Source: Cancer Network)
Source: Cancer Network - November 19, 2009 Category: Cancer & Oncology Source Type: info

Making the most of gastric imaging requires clear communication between oncologists and radiologistEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
There is a complex array of tests for imaging the abdomen, but there are really only three things that oncologists need to tell radiologists in order to get the most from these imaging studies, according to Fergus V. Coakley, MD, chief of abdominal imaging (Source: Cancer Network)
Source: Cancer Network - November 19, 2009 Category: Cancer & Oncology Source Type: info

Postsurgical H&N patients manage to complete radiotherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Head and neck patients who undergo surgery first are more likely to complete radiation therapy, according to Seattle-based researchers. Megan Dann Fesinmeyer, PhD, MPH, and colleagues noted that radiation dose and treatment duration correlated with tumor control and survival, but that breaks in radiotherapy have been associated with inferior tumor control. (Source: Cancer Network)
Source: Cancer Network - November 18, 2009 Category: Cancer & Oncology Source Type: info

Moving at the speed of scienceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Owen Witte, MD, has been a California resident for nearly 35 years, but there’s nothing laid-back about him. The director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research retains the rapid fire speech of a native New Yorker. Although it was getting toward late afternoon when Dr. Witte met with Oncology News International, he ushered a steady stream of visitors into and out of his office at the University of California, Los Angeles. When he spoke about his work, it was with the same energy that no doubt drew him to science in the first place. (Source: Cancer Network)
Source: Cancer Network - November 18, 2009 Category: Cancer & Oncology Source Type: info

International trials: Panitumumab delays disease progression in colon cancer metsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
BERLIN—A pair of colon cancer trials using panitumumab (Vectibix) not only proved the efficacy of the drug in patients with nonmutated KRAS but also highlighted the importance of ascertaining KRAS status. Trial 181 evaluated panitumumab in combination with FOLFIRI as a second-line treatment for metastatic colorectal cancer, while trial 203 paired the anti-EGFR agent with FOLFOX4 as first-line treatment. (Source: Cancer Network)
Source: Cancer Network - November 18, 2009 Category: Cancer & Oncology Source Type: info

Women with small HER2+ breast ca face recurrence riskEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Researchers in the U.S. and Italy report that women with HER2-positive breast cancers that are 1 cm or less in diameter and are node-negative have a risk of recurrence that is two to five times greater than that of women with HER2-negative breast cancers (J Clin Oncol online, November 2, 2009). (Source: Cancer Network)
Source: Cancer Network - November 17, 2009 Category: Cancer & Oncology Source Type: info

Imaging experts weigh in on screening controversyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Despite the hubbub, breast imaging researchers saw nothing new in the findings of Dr. Esserman’s group. Daniel Kopans, MD, a professor of radiology at Boston’s Massachusetts General Hospital, called her observation about mammography catching nonlethal cancers but missing aggressive ones “a fundamental concept that is older than I am. Mammography saves lives by finding moderate- and slow-growing cancer that will kill in five or more years without diagnosis and treatment,” according to Dr. Kopans. (Source: Cancer Network)
Source: Cancer Network - November 17, 2009 Category: Cancer & Oncology Source Type: info

Moderate marijuana use may tamp risk of H&N cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Cannabinoids, which are a byproduct of marijuana smoke, have been recognized to have potential antitumor properties, but evidence of a relationship between marijuana use and the induction of head and neck squamous cell carcinoma has been inconsistent. (Source: Cancer Network)
Source: Cancer Network - November 17, 2009 Category: Cancer & Oncology Source Type: info

PET gains medical and political traction in cancer prognosisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PET/CT is gaining recognition both medically and politically when it comes to sizing up cancer. And the timing for oncologists couldn’t be better. (Source: Cancer Network)
Source: Cancer Network - November 16, 2009 Category: Cancer & Oncology Source Type: info

Prometheus releases trio of tissue-specific microRNA testsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Prometheus Laboratories has launched the ProOncDx line of cancer diagnostic tests. ProOncDx TumorSource pinpoints the tissue of origin in metastatic tumors in a number of cancers including breast, brain, kidney, colon, liver, ovary, lung, pancreas, and prostate. The test measures the expression level of 48 microRNA biomarkers. (Source: Cancer Network)
Source: Cancer Network - November 16, 2009 Category: Cancer & Oncology Source Type: info

Pazopanib accepted by FDA as treatment for kidney cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
GlaxoSmithKline has received FDA approval for pazopanib (Votrient) for the treatment of patients with advanced renal cell carcinoma. The FDA’s approval of the angiogenesis inhibitor was based on data from a phase III clinical trial, which demonstrated that pazopanib reduced the risk of tumor progression or death by 54% compared with placebo and regardless of prior treatment. (Source: Cancer Network)
Source: Cancer Network - November 16, 2009 Category: Cancer & Oncology Source Type: info

Oncologists should look upon imaging as another biomarker, not just an anatomic pictureEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Annick Van den Abbeele, MD, couldn’t believe her eyes. Dr. Van den Abbeele, the chief of radiology at Boston’s Dana-Farber Cancer Institute, had seen the patient just a month earlier. At that time, the 35-year-old woman had a gastrointestinal stromal tumor in her abdomen that was so large, she looked six months’ pregnant. But at the patient’s follow up FDG-PET study, the tumor was completely gone. (Source: Cancer Network)
Source: Cancer Network - November 16, 2009 Category: Cancer & Oncology Source Type: info

Study: A/C chemo takes toll on bonesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The skeletal health of pre-menopausal women with estrogen receptor-negative breast cancer took a beating after six cycles of doxorubicin (Doxil)/cyclophosphamide (A/C) chemotherapy. (Source: Cancer Network)
Source: Cancer Network - November 16, 2009 Category: Cancer & Oncology Source Type: info

New molecule interferes with heat shock protein activitiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Researchers had identified a small molecule that inhibits the heat shock protein HSP70. They also demonstrated in their animal experiment that the HSP inhibitor could stop tumor formation and significantly extend survival. (Source: Cancer Network)
Source: Cancer Network - November 16, 2009 Category: Cancer & Oncology Source Type: info

FDA approves cervical cancer vaccineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Cervarix has won FDA approval for the prevention of cervical pre-cancers and cervical cancer associated with HPV-16 and HPV-18 for use in girls and young women (ages 10-25), according to GlaxoSmithKline. In clinical trials, the vaccine was shown to be 93% effective in the prevention of cervical pre-cancers associated with HPV -16 or 18, in women without evidence of current infection with, or prior exposure to, the same HPV type at the time of vaccination. (Source: Cancer Network)
Source: Cancer Network - November 16, 2009 Category: Cancer & Oncology Source Type: info

EC145 shows anti-tumor activity in ovarian cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
BELGRADE—Endocyte presented phase IIa data from its trial using EC145 (pegylated liposomal doxorubicin) in women with advanced-stage ovarian cancer at the 2009 European Society of Gynaecological Oncology. The study participants had a median o (Source: Cancer Network)
Source: Cancer Network - November 16, 2009 Category: Cancer & Oncology Source Type: info

Hysterecomy fails to offer better disease controlEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A modified radical hysterectomy (class II) did not improve locoregional control and survival compared with simple extrafascial abdominal hysterectomy (class I). Investigators from University of Milano-Bicocca in Monza, Italy, randomized 520 patients with stage I endometrial cancer to class I or class II surgery. They found that the median length of parametria and vagina removed were 15 mm and 5 mm respectively for class I hysterectomy vs 20 mm and 15 mm for class II hysterectomy (P > .001). Operating time and blood loss were statistically significantly higher for class II hysterectomy. Five-year disease-free survival and o...
Source: Cancer Network - November 16, 2009 Category: Cancer & Oncology Source Type: info

Turmeric may induce cell death in esophageal cancer sans apoptosisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Turmeric, or curcumin (diferuloylmethane), may be a favorable agent for the prevention and treatment of esophageal cancer, according to researchers at the Cork Cancer Research Center and Mercy University Hospital in Cork, Ireland. The authors noted that turmeric was able to induce cell death by a mechanism that is not reliant on apoptosis induction. (Source: Cancer Network)
Source: Cancer Network - November 16, 2009 Category: Cancer & Oncology Source Type: info

Astellas, Medivation team on prostate RxEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Astellas has partnered with Medivation to co-develop and market the oral anti-androgen, MDV3100. In September, Medivation enrolled patients in the phase III AFFIRM trial, which is evaluating MDV3100 in 1,200 men with castration-resistant prostate cancer who were previously treated with docetaxel (Doxil) chemotherapy. (Source: Cancer Network)
Source: Cancer Network - November 16, 2009 Category: Cancer & Oncology Source Type: info

Pain relief with radiation Rx may come at too high a priceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
An analysis by researchers at the University of Michigan Comprehensive Cancer Center shows that costs vary widely for different treatment regimens and from one delivery method to another. Yet receiving more treatments and spending extra on more sophisticated technology may do little good, at least when it comes to pain relief. (Source: Cancer Network)
Source: Cancer Network - November 16, 2009 Category: Cancer & Oncology Source Type: info

New technology unveiled at ASTRO 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CHICAGO—Accuray introduced the CyberKnife VSI System. The system is designed to also include conventionally fractionated robotic intensity-modulated radiation therapy. (Source: Cancer Network)
Source: Cancer Network - November 16, 2009 Category: Cancer & Oncology Source Type: info

Stereotactic body radiation controls lung ca in frail patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CHICAGO—In lung cancer patients, stereotactic body radiation therapy achieved a 98% local control rate that persisted over three years in those who were too frail with comorbidities to undergo surgery, according to research presented at ASTRO 2009. (Source: Cancer Network)
Source: Cancer Network - November 16, 2009 Category: Cancer & Oncology Source Type: info

Elitek FDA-approved for recombinant uricolytic agent for tumor lysisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Rasburicase (Elitek) has been granted FDA approval for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies. (Source: Cancer Network)
Source: Cancer Network - November 16, 2009 Category: Cancer & Oncology Source Type: info

Bone marrow aspiration enhances detection of leukemia cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Scientists in New Mexico are experimenting with a nanotechnology device that quantifies the amount of nanoparticle-bound tumor cells in a tissue sample and offers increased sensitivity to minimal residual disease (Cancer Res 69:6839-6847, 2009). (Source: Cancer Network)
Source: Cancer Network - November 16, 2009 Category: Cancer & Oncology Source Type: info

FDA fast tracks Rx for hard-to-treat peripheral T-cell lymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Allos Therapeutics has received accelerated FDA approval for Folotyn (pralatrexate) as a single-agent treatment in patients with relapsed or refractory peripheral T-cell lymphoma. (Source: Cancer Network)
Source: Cancer Network - November 16, 2009 Category: Cancer & Oncology Source Type: info

Infection control wins stimulus fundsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
An investigator at Fred Hutchinson Cancer Center in Seattle has earned a $1.74 million grant under the American Recovery & Reinvestment Act of 2009. (Source: Cancer Network)
Source: Cancer Network - November 16, 2009 Category: Cancer & Oncology Source Type: info

ASCO seeks to turbo charge cancer research with new reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Oncology is gaining ground on several fronts, thanks in large part to increased sophistication in the technology of cancer therapeutics, but also in how those technologies are applied. (Source: Cancer Network)
Source: Cancer Network - November 11, 2009 Category: Cancer & Oncology Source Type: info

Nilotinib Meets Primary Endpoint in Pivotal Trial Against Imatinib as First-Line Treatment in Chronic Myeloid Leukemia PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Novartis announced recently that nilotinib (Tasigna) 200-mg capsules met its primary endpoint in the first head-to-head comparison with the company’s groundbreaking drug imatinib mesylate (Gleevec) tablets. Nilotinib produced faster and deeper responses than imatinib when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Nilotinib was well tolerated in the study. (Source: Cancer Network)
Source: Cancer Network - November 10, 2009 Category: Cancer & Oncology Source Type: info

Phase III Data Show Octreotide Reduced Risk of Disease Progression by 66% in Advanced Neuroendocrine Tumor PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Data published in the Journal of Clinical Oncology show that patients with advanced neuroendocrine tumors (NET) of the midgut who were treated with octreotide acetate (Sandostatin LAR Depot) experienced a 66% reduction in risk of disease progression vs placebo. Octreotide is indicated to treat the diarrhea and flushing episodes associated with advanced carcinoid tumors. (Source: Cancer Network)
Source: Cancer Network - November 10, 2009 Category: Cancer & Oncology Source Type: info

Pazopanib Approved for Advanced Kidney CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The US Food and Drug Administration approved GlaxoSmithKline’s pazopanib (Votrient), the sixth drug to be approved for kidney cancer since 2005. (Source: Cancer Network)
Source: Cancer Network - November 10, 2009 Category: Cancer & Oncology Source Type: info

FDA Approves Cervical Cancer VaccineEmail this article to a colleague. Save this article to My Clippings. discuss this article 1 CommentDiscuss or comment on this article.
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline’s human papillomavirus bivalent (types 16 and 18) vaccine, recombinant (Cervarix) for the prevention of cervical precancers and cervical cancer associated with oncogenic human papillomavirus (HPV) types 16 and 18 for use in girls and young women (aged 10–25). Women are at risk of HPV infecti (Source: Cancer Network)
Source: Cancer Network - November 10, 2009 Category: Cancer & Oncology Source Type: info

Rasburicase Approved to Manage Complications of Anticancer TherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Sanofi-aventis US announced that the US Food and Drug Administration (FDA) has granted marketing approval for rasburicase (Elitek) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid. (Source: Cancer Network)
Source: Cancer Network - November 10, 2009 Category: Cancer & Oncology Source Type: info

Ofatumumab Receives Approval for CLLEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The US Food and Drug Administration approved ofatumumab (Arzerra) for patients with chronic lymphocytic leukemia (CLL) whose cancer is no longer being controlled by other forms of chemotherapy. The product was approved under the FDA’s accelerated approval process, which allows earlier approval of drugs that meet unmet medical needs. (Source: Cancer Network)
Source: Cancer Network - November 10, 2009 Category: Cancer & Oncology Source Type: info

Proton therapy report advises cautionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The limited evidence on the comparative effectiveness of proton-beam therapy, especially in comparison to other radiation-based treatment modalities, undermines the value of this up-and-coming technology, according to a comparative effectiveness report by the Agency for Healthcare Research and Quality. (Source: Cancer Network)
Source: Cancer Network - October 30, 2009 Category: Cancer & Oncology Source Type: info

Antidepressants continue to show increased inhibition of colorectal tumor cell growthEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Use of antidepressants, particularly selective serotonin reuptake inhibitors and possibly tricyclic antidepressants, is associated with a reduced risk of colorectal cancer, according to research by the Group Health Research Institute in Seattle. But it’s too soon to make specific recommendations on how to harness this potential value of these drugs in cancer prevention. (Source: Cancer Network)
Source: Cancer Network - October 29, 2009 Category: Cancer & Oncology Source Type: info

New class of alpha emitters takes aim at bone metastasesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A new class of cancer alpha-pharmaceuticals is approaching the marketplace, one built around the basis of radiotherapy itself. An isotope of radium, the element discovered more than a century ago by Pierre and Marie Curie, is the cornerstone of this new class of radiopharmaceuticals. (Source: Cancer Network)
Source: Cancer Network - October 29, 2009 Category: Cancer & Oncology Source Type: info

Cancer, not HPV vaccination, hastened death of UK girlEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Cancer killed a 14-year-old girl who died shortly after being given Cervarix as part of a national immunization program. Early reports speculated that there may have been a link between the shot and her death, but according to a coroner’s assessment, there was no indication that the culprit was the HPV vaccine, which is marketed by GlaxoSmithKline. The girl’s death was caused by malignant disease in the heart and lungs, according to the coroner’s report. (Source: Cancer Network)
Source: Cancer Network - October 29, 2009 Category: Cancer & Oncology Source Type: info

Who's NewsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The AACR has appointed George Prendergast, PhD, as the editor-in-chief of Cancer Research. He is the president and CEO of Lankenau Institute for Medical Research in Wynnewood, Penn., and previously served as a senior editor and deputy editor for the journal. Dr. Prendergast will take up the five-year editorship in January 2010 (Source: Cancer Network)
Source: Cancer Network - October 29, 2009 Category: Cancer & Oncology Source Type: info

Takeda nabs priority review for VelcadeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Takeda announced that the FDA has agreed to consider an expedited review of the company’s request to update its label for bortezomib (Velcade) to include long-term survival data in patients with previously untreated multiple myeloma. (Source: Cancer Network)
Source: Cancer Network - October 29, 2009 Category: Cancer & Oncology Source Type: info

Obesity hinders treatment in pediatric leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Obesity may contribute to chemotherapy resistance and increasing relapse rates among children with leukemia, an animal study in Cancer Research (online, September 22, 2009) suggests. (Source: Cancer Network)
Source: Cancer Network - October 29, 2009 Category: Cancer & Oncology Source Type: info

Posaconazole reduces infection in AML patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The incidence of pneumonia and invasive pulmonary aspergillosis in acute myeloid leukemia patients was reduced when they were given posaconazole (Noxafil) as prophylaxis. (Source: Cancer Network)
Source: Cancer Network - October 29, 2009 Category: Cancer & Oncology Source Type: info

Global report warns of escalating cancer rateEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A coalition of international cancer experts is warning that the global cancer burden will double over the next two decades with an increasing concentration of cases in low-income and middle-income countries. (Source: Cancer Network)
Source: Cancer Network - October 29, 2009 Category: Cancer & Oncology Source Type: info

Stop and smell the volatile organic compounds in lung caEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
SAN FRANCISCO—Studies have identified specific volatile organic compounds in the breath of lung cancer patients, but the origin of those compounds is still ambiguous: Are they from the tumor itself, the tumor micro- (Source: Cancer Network)
Source: Cancer Network - October 29, 2009 Category: Cancer & Oncology Source Type: info

Juice PlusEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Despite the widespread perception that dietary supplements are safe, few products have been subjected to rigorous research. The potential risks of dietary supplement use are not known. (Source: Cancer Network)
Source: Cancer Network - October 24, 2009 Category: Cancer & Oncology Source Type: info

Sorafenib Plus Chemotherapy Significantly Prolongs Progression-Free Survival in Advanced BreasEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc, announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo-controlled phase II trial showing that sorafenib (Nexavar) tablets in combination with the oral chemotherapeutic agent, capecitabine (Xeloda), significantly extended progression-free survival in patients with advanced breast cancer. (Source: Cancer Network)
Source: Cancer Network - October 23, 2009 Category: Cancer & Oncology Source Type: info

Surgical Removal of Primary Tumor Improves Survival in Metastatic Breast Cancer PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Removal of the primary breast tumor in women whose cancer has already metastasized can have a significant effect on their survival, Dutch researchers have found. Dr. Jetske Ruiterkamp, a surgical resident from the Jeroen Bosch Hospital, Den Bosch, The Netherlands, working under the supervision of Dr. Miranda Ernst, told Europe’s largest cancer congress, ECCO 15/ESMO 34, in Berlin that her research meant that women who were diagnosed at a late stage of the disease could expect to survive longer. (Source: Cancer Network)
Source: Cancer Network - October 23, 2009 Category: Cancer & Oncology Source Type: info